Integrated BioPharma (INBP) 10-Q 12 Feb 20 2020 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Dec. 31, 2019	Feb. 12, 2020
Document Information [Line Items]
Entity Registrant Name	INTEGRATED BIOPHARMA INC
Entity Central Index Key	0001016504
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		29,565,943
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Interactive Data Current	Yes

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Sales, net	$ 14,197	$ 12,001	$ 25,603	$ 22,305
Cost of sales	12,171	10,671	22,178	19,756
Gross profit	2,026	1,330	3,425	2,549
Selling and administrative expenses	821	843	1,744	1,657
Operating income	1,205	487	1,681	892
Other income (expense), net
Interest expense	(109)	(190)	(233)	(390)
Change in fair value of derivative liabilities				9
Unrealized loss on investments	(31)		(55)
Other income, net	6	7	27	7
Other income (expense), net	(134)	(183)	(261)	(374)
Income before income taxes	1,071	304	1,420	518
Provision for income taxes	112	58	149	113
Net income	$ 959	$ 246	$ 1,271	$ 405
Basic earnings per common share (in dollars per share)	$ 0.03	$ 0.01	$ 0.04	$ 0.01
Diluted earnings per common share (in dollars per share)	$ 0.03	$ 0.01	$ 0.04	$ 0.01
Weighted average common shares outstanding - basic (in shares)	29,565,943	29,392,030	29,565,943	28,305,408
Add: Equivalent shares outstanding (in shares)	1,025,020	506,327	1,042,300	600,837
Weighted average common shares outstanding - diluted (in shares)	30,590,963	29,898,357	30,608,243	28,906,245

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Current Assets:
Cash	$ 67	$ 475
Accounts receivable, net	4,879	4,439
Inventories	9,289	8,819
Other current assets	301	346
Total current assets	14,536	14,079
Property and equipment, net	1,720	1,778
Operating lease right-of-use assets	3,052	3,284
Deferred tax assets, net	577	534
Security deposits and other assets	86	115
Total Assets	19,971	19,790
Current Liabilities:
Advances under revolving credit facility	5,191	5,834
Accounts payable (includes $71 and $67 due to related party)	4,258	3,855
Accrued expenses and other current liabilities	1,220	1,147
Current portion of long term debt, net	1,146	1,047
Current portion of operating lease liabilities	478	470
Total current liabilities	12,293	12,353
Operating lease liabilities	2,580	2,822
Long term debt, net	1,904	2,722
Total liabilities	16,777	17,897
Commitments and Contingencies
Stockholders' Equity :
Common Stock, $0.002 par value; 50,000,000 shares authorized; 29,600,843 shares issued and 29,565,943 shares outstanding, respectively	59	59
Additional paid-in capital	50,227	50,197
Accumulated deficit	(46,993)	(48,264)
Less: Treasury stock, at cost, 34,900 shares	(99)	(99)
Total Stockholders' Equity	3,194	1,893
Total Liabilities and Stockholders' Equity	$ 19,971	$ 19,790

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Operating lease right-of-use assets	$ 3,052	$ 3,284
Accounts payable, related parties	71	67
Current portion of operating lease liabilities	478	470
Operating lease liabilities	$ 2,580	$ 2,822
Common stock, par value (in dollars per share)	$ 0.002	$ 0.002
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	29,600,843	29,600,843
Common stock, shares outstanding (in shares)	29,565,943	29,565,943
Treasury stock, shares (in shares)	34,900	34,900
Vitamin Realty LLC [Member]
Operating lease right-of-use assets	$ 3,014	$ 3,236
Current portion of operating lease liabilities	458	450
Operating lease liabilities	$ 2,563	$ 2,793

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficiency) (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Jun. 30, 2018	21,170,074			34,900
Balance at Jun. 30, 2018	$ 42	$ 44,773	$ (49,952)	$ (99)	$ (5,236)
Net income			159		159
Shares issued upon conversion of CD Financial, LLC Convertible Note, net (in shares)	8,230,769
Shares issued upon conversion of CD Financial, LLC Convertible Note, net	$ 17	5,256			5,273
Balance (in shares) at Sep. 30, 2018	29,400,843			34,900
Balance at Sep. 30, 2018	$ 59	50,029	(49,793)	$ (99)	196
Balance (in shares) at Jun. 30, 2018	21,170,074			34,900
Balance at Jun. 30, 2018	$ 42	44,773	(49,952)	$ (99)	(5,236)
Net income					405
Balance (in shares) at Dec. 31, 2018	29,600,843			34,900
Balance at Dec. 31, 2018	$ 59	50,053	(49,547)	$ (99)	466
Balance (in shares) at Sep. 30, 2018	29,400,843			34,900
Balance at Sep. 30, 2018	$ 59	50,029	(49,793)	$ (99)	196
Net income			246		246
Shares issued upon exercise of employee stock options (in shares)	200,000
Shares issued upon exercise of employee stock options		24			24
Balance (in shares) at Dec. 31, 2018	29,600,843			34,900
Balance at Dec. 31, 2018	$ 59	50,053	(49,547)	$ (99)	466
Balance (in shares) at Jun. 30, 2019	29,600,843			34,900
Balance at Jun. 30, 2019	$ 59	50,197	(48,264)	$ (99)	1,893
Stock compensation expense for employee stock options		15			15
Net income			312		312
Balance (in shares) at Sep. 30, 2019	29,600,843			34,900
Balance at Sep. 30, 2019	$ 59	50,212	(47,952)	$ (99)	2,220
Balance (in shares) at Jun. 30, 2019	29,600,843			34,900
Balance at Jun. 30, 2019	$ 59	50,197	(48,264)	$ (99)	1,893
Net income					1,271
Balance (in shares) at Dec. 31, 2019	29,600,843			34,900
Balance at Dec. 31, 2019	$ 59	50,227	(46,993)	$ (99)	3,194
Balance (in shares) at Sep. 30, 2019	29,600,843			34,900
Balance at Sep. 30, 2019	$ 59	50,212	(47,952)	$ (99)	2,220
Stock compensation expense for employee stock options		15			15
Net income			959		959
Balance (in shares) at Dec. 31, 2019	29,600,843			34,900
Balance at Dec. 31, 2019	$ 59	$ 50,227	$ (46,993)	$ (99)	$ 3,194

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows provided by operating activities:
Net income	$ 1,271	$ 405
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	160	166
Amortization of operating lease right-of-use assets	233	224
Stock based compensation	30
Change in deferred tax assets	(43)	12
Unrealized loss on investments	55
Other, net	7	23
Changes in operating assets and liabilities:
Accounts receivable	(441)	(721)
Inventories	(471)	(3,794)
Other current assets	(10)	(47)
Security deposits and other assets	24	(4)
Accounts payable	403	2,989
Accrued expenses and other liabilities	73	58
Operating lease obligations	(233)	(225)
Net cash provided by (used in) operating activities	1,058	(914)
Cash flows from investing activities:
Purchase of property and equipment	(101)	(287)
Proceeds from sale of machinery and equipment	3
Cash contribution in AgroSport LLC		(7)
Net cash used in investing activities	(98)	(294)
Cash flows from financing activities:
Advances under revolving credit facility	23,826	22,899
Proceeds from exercise of employee stock options		24
Repayments of advances under revolving credit facility	(24,469)	(21,467)
Repayments under term note payables	(610)	(330)
Repayments under finance lease obligations	(115)	(101)
Net cash (used in) provided by financing activities	(1,368)	1,025
Net increase in cash	(408)	(183)
Cash at beginning of period	475	228
Cash at end of period	67	45
Interest paid	228	369
Income taxes paid	$ 155	$ 123

Note 1 - Principles of Consolid

Note 1 - Principles of Consolidation and Basis of Presentation	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Basis of Presentation of Interim Financial Statements The accompanying condensed consolidated financial statements for the interim periods are unaudited and include the accounts of Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”). The interim condensed consolidated financial statements have been prepared in conformity with Rule 8 03 X not 10 June 30, 2019 ( 10 June 30, 2019 not three six December 31, 2019 not June 30, 2020 Reclassifications. Nature of Operations The Company is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States, Luxembourg and Canada. The Company was previously known as Integrated Health Technologies, Inc. and, prior to that, as Chem International, Inc. The Company was reincorporated in its current form in Delaware in 1995. The Company’s business segments include: (a) Contract Manufacturing operated by Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; (b) Branded Proprietary Products operated by AgroLabs, Inc. (“AgroLabs”), which distributes healthful nutritional products for sale through major mass market, grocery and drug and vitamin retailers, under the following brands: Peaceful Sleep, Green Envy, Wheatgrass and other products which are being introduced into the market (these are referred to as our branded proprietary nutraceutical business and/or products); and (c) Other Nutraceutical Businesses which includes the operations of (i) The Vitamin Factory (the “Vitamin Factory”), which sells private label MDC products, as well as our AgroLabs products, through the Internet, (ii) IHT Health Products, Inc. (“IHT”) a distributor of fine botanicals, including multi minerals produced under a license agreement, (iii) MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfilment services and (iv) Chem International, Inc. (“Chem”), a distributor of certain raw materials for DSM Nutritional Products LLC. Accounting Policies Accounting Pronouncements Recently Adopted In October, 2016, No. 2016 16, 740 July 1, 2019. not In July 2017, 2017 11, 260 480 815 July 1, 2019 June 30, 2020, not Aside from the adoption of ASUs, as described above, there have been no 2020 10 June 30, 2019. Significant Accoun ting P olicies Revenue Recognition. 606, five ● identification of the promised goods or services in the contract; ● determination of whether the promised goods or serves are performance obligations including whether they are distinct in the context of the contract; ● measurement of the transaction price, including the constraint on variable consideration; ● allocation of the transaction price to the performance obligations based on estimated selling prices; and ● recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise to transfer a distinct good or service to the customer and is the unit of account in ASC 606. Leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not may We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component. Earnings Per Share. The following options were not three six December 31, 2019 2018: Three Months Ended Six Months Ended December 31, December 31, 2019 2018 2019 2018 Anti-dilutive stock options 50,000 150,000 50,000 150,000 Total anti-dilutive shares 50,000 150,000 50,000 150,000

Note 2 - Inventories

Note 2 - Inventories	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 2 . Inventories Inventories are stated at the lower of cost or net realizable value using the first first December 31, June 30, 2019 2019 Raw materials $ 5,716 $ 4,550 Work-in-process 2,703 2,325 Finished goods 870 1,944 Total $ 9,289 $ 8,819

Note 3 - Property and Equipment

Note 3 - Property and Equipment, Net	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 3 . Property and Equipment, net Property and equipment, net consists of the following: December 31, June 30, 2019 2019 Land and building $ 1,250 $ 1,250 Leasehold improvements 1,282 1,282 Machinery and equipment 6,376 6,280 Transportation equipment 6 6 8,914 8,818 Less: Accumulated depreciation and amortization (7,194 ) (7,040 ) Total $ 1,720 $ 1,778 Depreciation and amortization expense recorded on property and equipment was $69 $66 three $160 $132 six December 31, 2019 2018, $6 $38 six December 31, 2019 2018, $3 $0 six December 31, 2019 2018,

Note 4 - Senior Credit Facility

Note 4 - Senior Credit Facility and Other Long Term Debt	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 4 . Senior Credit Facility and other Long Term Debt As of December 31, 2019 June 30, 2019, Principal Amount Interest Rate Maturity Date As of December 31, 2019 As of June 30, 2019 Revolving advances under Senior Credit Facility with PNC Bank, National Association $ 5,191 $ 5,834 * 5/15/2024 Installment Note with PNC Bank 2,941 3,542 * 5/15/2024 Installment Note with PNC Equipment Finance - 8 4.57 % 7/29/2019 Capitalized lease obligations 154 269 4.01% 9.38 % 2/20/2019 - 12/9/2020 Total outstanding debt 8,286 9,653 Less: Revolving Advances (5,191 ) (5,834 ) Prepaid financing costs (45 ) (50 ) Current portion of long term debt, net (1,146 ) (1,047 ) Long term debt, net $ 1,904 $ 2,722 * See table below SENIOR CREDIT FACILITY On May 15, 2019, June 27, 2012, February 19, 2016, May 15, 2019. The Amended Loan Agreement provides for a total of $11,585 $8,000 $3,585 2.50%. 3.00%. As of December 31, 2019 June 30, 2019, $4,500 $4,250 $2,852 $3,455 December 31, 2019 June 30, 2019 2.50% 3.00% December 31, June 30, 2019 2019 Revolving Credit Facility: Base Rate Interest 4.75 % 5.50 % Eurodollar Rate 4.30475 % 4.881 % Term Loan: Base Rate Interest 5.00 % 5.75 % Eurodollar Rate 4.792% and 4.80475 % 5.381% and 5.3838 % Upon and after the occurrence of any event of default under the Amended Loan Agreement, and during the continuation thereof, interest shall be payable at the interest rate then applicable plus 2%. May 15, 2024 ( The principal balance of the Revolving Advances is payable on the Senior Maturity Date, subject to acceleration, based upon a material adverse event clause, as defined, subjective accelerations for borrowing base reserves, as defined or upon the occurrence of any event of default under the Amended Loan Agreement or earlier termination of the Amended Loan Agreement pursuant to the terms thereof. The Term Loan shall be repaid in eighty-four 84 first eighty-three 83 $43, first June, 2019, first The Revolving Advances are subject to the terms and conditions set forth in the Amended Loan Agreement and are made in aggregate amounts at any time equal to the lesser of ( x $8,000 85%, 75%, 85% inventory appraisal reasonably satisfactory to PNC in its sole discretion exercised in good faith) and (C) the inventory sublimit in the aggregate at any one may The Amended Loan Agreement contains customary mandatory prepayment provisions, including, without limitation the requirement to use any sales proceeds from the sale of iBio Stock to repay the Term Loan and to prepay the outstanding amount of the Term Note in an amount equal to twenty-five 25% June 30, 2016, not one hundred twenty 120 December 31, 2019, 25% June 30, 2016. In connection with the Senior Credit Facility, the following loan documents were executed: (i) a Stock Pledge Agreement with PNC, pursuant to which the Company pledged to PNC the iBio Stock; (ii) a Mortgage and Security Agreement with PNC with IHT Properties; and (iii) an Environmental Indemnity Agreement with PNC. OTHER LONG TERM DEBT Capitalized Lease Obligations. November 1, 2019, December 22, 2017 $143, $6 6.56%.

Note 5 - Significant Risks and

Note 5 - Significant Risks and Uncertainties	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 5. ( a ) Major Customers. three December 31, 2019 2018, 93% two two 70% 26% 75% 20% three December 31, 2019 2018, six December 31, 2019 2018, 92% 91% two two 68% 27% six December 31, 2019 70% 24% six December 31, 2018, two 89% 88% December 31 June 30, 2019, 10% ( b ) Other Business Risks. 73% September 1, 2018 August 31, 2021.

Note 6 - Leases and Other Commi

Note 6 - Leases and Other Commitments and Contingencies	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 6. (a) Leases. 1 8 The components of lease expense for the three December 31, 2019 2018, 2019 2018 Related Party - Vitamin Realty Other Leases Totals Related Party - Vitamin Realty Other Leases Totals Operating lease costs $ 142 $ 25 $ 167 $ 142 $ 27 $ 169 Finance Operating Lease Costs: Amortization of right-of use assets $ - $ 2 $ 2 $ - $ 16 $ 16 Interest on operating lease liabilities - 3 3 - 3 3 Total finance lease cost $ - $ 5 $ 5 $ - $ 19 $ 19 The components of lease expense for the six December 31, 2019 2018, 2019 2018 Related Party - Vitamin Realty Other Leases Totals Related Party - Vitamin Realty Other Leases Totals Operating lease costs $ 283 $ 56 $ 339 $ 283 $ 49 $ 332 Finance Operating Lease Costs: Amortization of right-of use assets $ - $ 29 $ 29 $ - $ 33 $ 33 Interest on operating lease liabilities - 8 8 - 7 7 Total finance lease cost $ - $ 37 $ 37 $ - $ 40 $ 40 Operating Lease Liabilities Related Party Operating L e ase Liabilities . 100% January 5, 2012, second 74,898 76,161 January 31, 2026. $533, May 19, 2014, January 5, 2012, 2,700 January 31, 2019 June 1, 2024. $27 Rent expense and lease amortization costs for the three December 31, 2019 2018 $220 $219, $431 $421 six December 31, 2019 2018, December 31, 2019 June 30, 2019, $71 $67, $3,021 $3,243 December 31, 2019 June 30, 2019, Other Operating Lease Liabilities . May, 2023, As of December 31, 2019, Right-of-use Assets Current Portion of Operating Lease Obligations Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 3,014 $ 458 $ 2,563 $ 3,385 Machinery and equipment leases 21 11 10 22 Office equipment leases 17 9 7 18 $ 3,052 $ 478 $ 2,580 $ 3,425 As of June 30, 2019, Right-of-use Assets Current Portion Operating Lease Obligations Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 3,236 $ 450 $ 2,793 $ 3,668 Machinery and equipment leases 26 11 15 27 Office equipment leases 22 9 14 24 $ 3,284 $ 470 $ 2,822 $ 3,719 As of December 31, 2019 June 30, 2019, 3.75% 3.76% 5.9 6.4 Supplemental cash flows information related to leases for the six December 31, 2019, Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 283 $ 47 $ 330 Operating cash flows from finance leases - 8 8 Financing cash flows from finance lease obligations - 115 115 Supplemental cash flows information related to leases for the six December 31, 2018, Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 285 $ 49 $ 334 Operating cash flows from finance leases - 7 7 Financing cash flows from finance lease obligations - 101 101 In the six December 31, 2019, one $25. Maturities of operating lease liabilities as of December 31, 2019 Operating Related Party Capitalized Lease Operating Lease Lease Year ending June 30, Commitment Commitment Obligations Total 2020, remaining $ 11 $ 283 $ 83 $ 377 2021 21 565 77 663 2022 8 565 - 573 2023 - 565 - 565 2024 - 563 - 563 2025 - 533 - 533 Thereafter - 311 - 311 Total minimum lease payments 40 3,385 160 3,585 Imputed interest (3 ) (364 ) (6 ) (373 ) Total $ 37 $ 3,021 $ 154 $ 3,212 Total rent expense, lease amortization costs and interest expense, including real estate taxes and maintenance charges, was approximately $262 $261 $526 $507 three six December 31, 2019 2018, ( b ) Legal Proceedings. The Company is subject, from time to time, to claims by third

Note 7 - Related Party Transact

Note 7 - Related Party Transactions	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 7. See Note 6

Note 8 - Segment Information an

Note 8 - Segment Information and Disaggregated Revenue	6 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 8. and Disaggregated Revenue The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments. The Company has divided its operations into three three December 31, 2019 2018 $2,319 $1,274, six December 31, 2019 2018 $4,345 $2,513, Financial information relating to the three December 31, 2019 2018 Sales, Net Segment U.S. International Gross Capital Customers Customers Total Profit (loss) Depreciation Expenditures Contract Manufacturing 2019 $ 11,501 $ 2,303 $ 13,804 $ 1,927 $ 69 $ 43 2018 10,498 1,258 11,756 1,246 66 269 Branded Proprietary Products 2019 2 - 2 (27 ) - - 2018 48 12 60 21 - - Other Nutraceutical Businesses 2019 375 16 391 126 - - 2018 181 4 185 63 - - Total Company 2019 11,878 2,319 14,197 2,026 69 43 2018 10,727 1,274 12,001 1,330 66 269 Financial information relating to the six December 31, 2019 2018 Sales, Net Segment U.S. International Gross Capital Customers Customers Total Profit (Loss) Depreciation Expenditures Contract Manufacturing 2019 $ 20,502 $ 4,286 $ 24,788 $ 3,177 $ 159 $ 101 2018 19,153 2,455 21,608 2,328 131 287 Branded Proprietary Products 2019 4 10 14 (30 ) - - 2018 119 19 138 42 - - Other Nutraceutical Businesses 2019 752 49 801 278 1 - 2018 520 39 559 179 1 - Total Company 2019 21,258 4,345 25,603 3,425 160 101 2018 19,792 2,513 22,305 2,549 132 287 Total Assets as of December 31, June 30, 2019 2019 Contract Manufacturing $ 18,017 $ 17,580 Branded Proprietary Products 395 427 Other Nutraceutical Businesses 1,559 1,783 Total Company $ 19,971 $ 19,790

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation of Interim Financial Statements The accompanying condensed consolidated financial statements for the interim periods are unaudited and include the accounts of Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”). The interim condensed consolidated financial statements have been prepared in conformity with Rule 8 03 X not 10 June 30, 2019 ( 10 June 30, 2019 not three six December 31, 2019 not June 30, 2020
Reclassification, Policy [Policy Text Block]	Reclassifications.
Nature of Operations [Policy Text Block]	Nature of Operations The Company is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States, Luxembourg and Canada. The Company was previously known as Integrated Health Technologies, Inc. and, prior to that, as Chem International, Inc. The Company was reincorporated in its current form in Delaware in 1995. The Company’s business segments include: (a) Contract Manufacturing operated by Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; (b) Branded Proprietary Products operated by AgroLabs, Inc. (“AgroLabs”), which distributes healthful nutritional products for sale through major mass market, grocery and drug and vitamin retailers, under the following brands: Peaceful Sleep, Green Envy, Wheatgrass and other products which are being introduced into the market (these are referred to as our branded proprietary nutraceutical business and/or products); and (c) Other Nutraceutical Businesses which includes the operations of (i) The Vitamin Factory (the “Vitamin Factory”), which sells private label MDC products, as well as our AgroLabs products, through the Internet, (ii) IHT Health Products, Inc. (“IHT”) a distributor of fine botanicals, including multi minerals produced under a license agreement, (iii) MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfilment services and (iv) Chem International, Inc. (“Chem”), a distributor of certain raw materials for DSM Nutritional Products LLC.
New Accounting Pronouncements, Policy [Policy Text Block]	Accounting Pronouncements Recently Adopted In October, 2016, No. 2016 16, 740 July 1, 2019. not In July 2017, 2017 11, 260 480 815 July 1, 2019 June 30, 2020, not Aside from the adoption of ASUs, as described above, there have been no 2020 10 June 30, 2019.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition. 606, five ● identification of the promised goods or services in the contract; ● determination of whether the promised goods or serves are performance obligations including whether they are distinct in the context of the contract; ● measurement of the transaction price, including the constraint on variable consideration; ● allocation of the transaction price to the performance obligations based on estimated selling prices; and ● recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise to transfer a distinct good or service to the customer and is the unit of account in ASC 606.
Lessee, Leases [Policy Text Block]	Leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not may We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component.
Earnings Per Share, Policy [Policy Text Block]	Earnings Per Share. The following options were not three six December 31, 2019 2018: Three Months Ended Six Months Ended December 31, December 31, 2019 2018 2019 2018 Anti-dilutive stock options 50,000 150,000 50,000 150,000 Total anti-dilutive shares 50,000 150,000 50,000 150,000

Note 1 - Principles of Consol_2

Note 1 - Principles of Consolidation and Basis of Presentation (Tables)	6 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended Six Months Ended December 31, December 31, 2019 2018 2019 2018 Anti-dilutive stock options 50,000 150,000 50,000 150,000 Total anti-dilutive shares 50,000 150,000 50,000 150,000

Note 2 - Inventories (Tables)

Note 2 - Inventories (Tables)	6 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, June 30, 2019 2019 Raw materials $ 5,716 $ 4,550 Work-in-process 2,703 2,325 Finished goods 870 1,944 Total $ 9,289 $ 8,819

Note 3 - Property and Equipme_2

Note 3 - Property and Equipment, Net (Tables)	6 Months Ended
	Dec. 31, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, June 30, 2019 2019 Land and building $ 1,250 $ 1,250 Leasehold improvements 1,282 1,282 Machinery and equipment 6,376 6,280 Transportation equipment 6 6 8,914 8,818 Less: Accumulated depreciation and amortization (7,194 ) (7,040 ) Total $ 1,720 $ 1,778

Note 4 - Senior Credit Facili_2

Note 4 - Senior Credit Facility and Other Long Term Debt (Tables)	6 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Debt [Table Text Block]	Principal Amount Interest Rate Maturity Date As of December 31, 2019 As of June 30, 2019 Revolving advances under Senior Credit Facility with PNC Bank, National Association $ 5,191 $ 5,834 * 5/15/2024 Installment Note with PNC Bank 2,941 3,542 * 5/15/2024 Installment Note with PNC Equipment Finance - 8 4.57 % 7/29/2019 Capitalized lease obligations 154 269 4.01% 9.38 % 2/20/2019 - 12/9/2020 Total outstanding debt 8,286 9,653 Less: Revolving Advances (5,191 ) (5,834 ) Prepaid financing costs (45 ) (50 ) Current portion of long term debt, net (1,146 ) (1,047 ) Long term debt, net $ 1,904 $ 2,722
Schedule of Debt Interest Rates [Table Text Block]	December 31, June 30, 2019 2019 Revolving Credit Facility: Base Rate Interest 4.75 % 5.50 % Eurodollar Rate 4.30475 % 4.881 % Term Loan: Base Rate Interest 5.00 % 5.75 % Eurodollar Rate 4.792% and 4.80475 % 5.381% and 5.3838 %

Note 6 - Leases and Other Com_2

Note 6 - Leases and Other Commitments and Contingencies (Tables)	6 Months Ended
	Dec. 31, 2019
Notes Tables
Lease, Cost [Table Text Block]	2019 2018 Related Party - Vitamin Realty Other Leases Totals Related Party - Vitamin Realty Other Leases Totals Operating lease costs $ 142 $ 25 $ 167 $ 142 $ 27 $ 169 Finance Operating Lease Costs: Amortization of right-of use assets $ - $ 2 $ 2 $ - $ 16 $ 16 Interest on operating lease liabilities - 3 3 - 3 3 Total finance lease cost $ - $ 5 $ 5 $ - $ 19 $ 19 2019 2018 Related Party - Vitamin Realty Other Leases Totals Related Party - Vitamin Realty Other Leases Totals Operating lease costs $ 283 $ 56 $ 339 $ 283 $ 49 $ 332 Finance Operating Lease Costs: Amortization of right-of use assets $ - $ 29 $ 29 $ - $ 33 $ 33 Interest on operating lease liabilities - 8 8 - 7 7 Total finance lease cost $ - $ 37 $ 37 $ - $ 40 $ 40
Leases and Remaining Commitments [Table Text Block]	Right-of-use Assets Current Portion of Operating Lease Obligations Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 3,014 $ 458 $ 2,563 $ 3,385 Machinery and equipment leases 21 11 10 22 Office equipment leases 17 9 7 18 $ 3,052 $ 478 $ 2,580 $ 3,425 Right-of-use Assets Current Portion Operating Lease Obligations Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 3,236 $ 450 $ 2,793 $ 3,668 Machinery and equipment leases 26 11 15 27 Office equipment leases 22 9 14 24 $ 3,284 $ 470 $ 2,822 $ 3,719
Supplemental Cash Flow Information, Leases [Table Text Block]	Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 283 $ 47 $ 330 Operating cash flows from finance leases - 8 8 Financing cash flows from finance lease obligations - 115 115 Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 285 $ 49 $ 334 Operating cash flows from finance leases - 7 7 Financing cash flows from finance lease obligations - 101 101
Lessee, Operating Lease and Finance Lease, Liability, Maturity [Table Text Block]	Operating Related Party Capitalized Lease Operating Lease Lease Year ending June 30, Commitment Commitment Obligations Total 2020, remaining $ 11 $ 283 $ 83 $ 377 2021 21 565 77 663 2022 8 565 - 573 2023 - 565 - 565 2024 - 563 - 563 2025 - 533 - 533 Thereafter - 311 - 311 Total minimum lease payments 40 3,385 160 3,585 Imputed interest (3 ) (364 ) (6 ) (373 ) Total $ 37 $ 3,021 $ 154 $ 3,212

Note 8 - Segment Information _2

Note 8 - Segment Information and Disaggregated Revenue (Tables)	6 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Sales, Net Segment U.S. International Gross Capital Customers Customers Total Profit (loss) Depreciation Expenditures Contract Manufacturing 2019 $ 11,501 $ 2,303 $ 13,804 $ 1,927 $ 69 $ 43 2018 10,498 1,258 11,756 1,246 66 269 Branded Proprietary Products 2019 2 - 2 (27 ) - - 2018 48 12 60 21 - - Other Nutraceutical Businesses 2019 375 16 391 126 - - 2018 181 4 185 63 - - Total Company 2019 11,878 2,319 14,197 2,026 69 43 2018 10,727 1,274 12,001 1,330 66 269 Sales, Net Segment U.S. International Gross Capital Customers Customers Total Profit (Loss) Depreciation Expenditures Contract Manufacturing 2019 $ 20,502 $ 4,286 $ 24,788 $ 3,177 $ 159 $ 101 2018 19,153 2,455 21,608 2,328 131 287 Branded Proprietary Products 2019 4 10 14 (30 ) - - 2018 119 19 138 42 - - Other Nutraceutical Businesses 2019 752 49 801 278 1 - 2018 520 39 559 179 1 - Total Company 2019 21,258 4,345 25,603 3,425 160 101 2018 19,792 2,513 22,305 2,549 132 287
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	Total Assets as of December 31, June 30, 2019 2019 Contract Manufacturing $ 18,017 $ 17,580 Branded Proprietary Products 395 427 Other Nutraceutical Businesses 1,559 1,783 Total Company $ 19,971 $ 19,790

Note 1 - Principles of Consol_3

Note 1 - Principles of Consolidation and Basis of Presentation - Antidilutive Securities Excluded From Weighted Average Diluted Common Shares Outstanding (Details) - shares	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Anti-dilutive shares (in shares)	50,000	150,000	50,000	150,000
Share-based Payment Arrangement, Option [Member]
Anti-dilutive shares (in shares)	50,000	150,000	50,000	150,000

Note 2 - Inventories - Inventor

Note 2 - Inventories - Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Raw materials	$ 5,716	$ 4,550
Work-in-process	2,703	2,325
Finished goods	870	1,944
Total	$ 9,289	$ 8,819

Note 3 - Property and Equipme_3

Note 3 - Property and Equipment, Net (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Depreciation, Total	$ 69,000	$ 66,000	$ 160,000	$ 132,000
Property, Plant and Equipment, Disposals			6,000	38,000
Gain (Loss) on Disposition of Property Plant Equipment, Total			$ 3,000	$ 0

Note 3 - Property and Equipme_4

Note 3 - Property and Equipment, Net - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Property and equipment, gross	$ 8,914	$ 8,818
Less: Accumulated depreciation and amortization	(7,194)	(7,040)
Total	1,720	1,778
Land and Building [Member]
Property and equipment, gross	1,250	1,250
Leasehold Improvements [Member]
Property and equipment, gross	1,282	1,282
Machinery and Equipment [Member]
Property and equipment, gross	6,376	6,280
Transportation Equipment [Member]
Property and equipment, gross	$ 6	$ 6

Note 4 - Senior Credit Facili_3

Note 4 - Senior Credit Facility and Other Long Term Debt (Details Textual) - USD ($) $ in Thousands	May 15, 2019	Dec. 22, 2017	Dec. 31, 2019	Jun. 30, 2019
Capital Lease Obligations, Total			$ 154	$ 269
First American Equipment Finance [Member]
Capital Lease Obligations, Total		$ 143
Sale Leaseback Transaction, Monthly Rental Payments		$ 6
Sale Leaseback Transaction, Imputed Interest Rate		6.56%
Amended Loan Agreement [Member]
Senior Notes, Total	$ 11,585
Debt Instrument, Debt Default, Interest Rate Basic Spread	2.00%
Line of Credit Facility Covenant Prepayment Provisions Percentage of Excess Cash flow			25.00%
Amended Loan Agreement [Member] | Term Loan [Member]
Debt Instrument, Face Amount	$ 3,585
Loans Payable, Noncurrent, Total			$ 2,852	3,455
Number of Consecutive Monthly Installments	84
Number of Consecutive Monthly Installments, Fixed Amount	83
Debt Instrument, Periodic Payment, Total	$ 43
Line of Credit Facility Covenant Prepayment Provisions Percentage of Excess Cash flow	25.00%
Amended Loan Agreement [Member] | Term Loan [Member] | Eurodollar [Member]
Debt Instrument, Basis Spread on Variable Rate	3.00%
Amended Loan Agreement [Member] | Term Loan [Member] | Base Rate [Member]
Debt Instrument, Basis Spread on Variable Rate			3.00%
Amended Loan Agreement [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 8,000
Long-term Line of Credit, Total			$ 4,500	$ 4,250
Line of Credit Facility Covenant Maximum Aggregate Revolving Advance	$ 8,000,000
Line of Credit Facility Covenant Aggregate Revolving Advance Receivables Advance Rate	85.00%
Line of Credit Facility Covenant Aggregate Revolving Advance Inventory Advance Rate	75.00%
Line of Credit Facility, Covenan,t Aggregate Revolving Advance, Appraised Liquidation Value, Inventory Advance Rate	85.00%
Amended Loan Agreement [Member] | Revolving Credit Facility [Member] | Eurodollar [Member]
Debt Instrument, Basis Spread on Variable Rate	2.50%
Amended Loan Agreement [Member] | Revolving Credit Facility [Member] | Base Rate [Member]
Debt Instrument, Basis Spread on Variable Rate			2.50%

Note 4 - Senior Credit Facili_4

Note 4 - Senior Credit Facility and Other Long Term Debt - Debt Outstanding (Details) - USD ($) $ in Thousands		6 Months Ended
		Dec. 31, 2019	Jun. 30, 2019
Capitalized lease obligations		$ 154	$ 269
Total outstanding debt		8,286	9,653
Prepaid financing costs		(45)	(50)
Current portion of long term debt, net		(1,146)	(1,047)
Long term debt, net		1,904	2,722
Convertible Debt [Member]
Current portion of long term debt, net		$ (1,146)	(1,047)
Minimum [Member]
Capitalized lease obligations, interest rate		4.01%
Capitalized lease obligations, maturity start date		Feb. 20, 2019
Maximum [Member]
Capitalized lease obligations, interest rate		9.38%
Capitalized lease obligations, maturity end date		Dec. 9, 2020
Revolving Advances [Member]
Notes Payable		$ 5,191	5,834
Interest Rate	[1]
Maturity Date		May 15, 2024
Less: Revolving Advances		$ (5,191)	(5,834)
Installment Note with PNC Bank [Member]
Notes Payable		$ 2,941	3,542
Interest Rate	[1]
Maturity Date		May 15, 2024
PNC Equipment Finance LLC [Member]
Notes Payable			$ 8
Interest Rate		4.57%
Maturity Date		Jul. 29, 2019
[1]	See table below

Note 4 - Senior Credit Facili_5

Note 4 - Senior Credit Facility and Other Long Term Debt - Interest Rates (Details)	Dec. 31, 2019	Jun. 30, 2019
Revolving Credit Facility [Member] | Base Rate [Member]
Interest rate	4.75%	5.50%
Revolving Credit Facility [Member] | Eurodollar [Member]
Interest rate	4.30475%	4.881%
Term Loan [Member] | Base Rate [Member]
Interest rate	5.00%	5.75%
Term Loan [Member] | Eurodollar [Member] | Minimum [Member]
Interest rate	4.792%	5.381%
Term Loan [Member] | Eurodollar [Member] | Maximum [Member]
Interest rate	4.80475%	5.3838%

Note 5 - Significant Risks an_2

Note 5 - Significant Risks and Uncertainties (Details Textual)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019
Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Number of Major Customers	2	2	2	2
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Contract Manufacturing [Member]
Number of Major Customers	2	2
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Customers [Member]
Concentration Risk, Percentage	93.00%	93.00%	92.00%	91.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 1 [Member]
Concentration Risk, Percentage			68.00%	70.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 1 [Member] | Contract Manufacturing [Member]
Concentration Risk, Percentage	70.00%	75.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 2 [Member]
Concentration Risk, Percentage			27.00%	24.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 2 [Member] | Contract Manufacturing [Member]
Concentration Risk, Percentage	26.00%	20.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Number of Major Customers			2		2
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member]
Concentration Risk, Percentage			89.00%		88.00%
Number of Employees, Geographic Area [Member] | Unionized Employees Concentration Risk [Member]
Concentration Risk, Percentage			73.00%

Note 6 - Leases and Other Com_3

Note 6 - Leases and Other Commitments and Contingencies (Details Textual) $ in Thousands	May 19, 2014USD ($)ft²	Jan. 05, 2012USD ($)ft²	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Jun. 30, 2019USD ($)
Operating Leases, Rent Expense, Net, Total			$ 262	$ 261	$ 507	$ 526
Unrelated Party [Member]
Operating Lease, Liability, Total			$ 37		$ 37
Lessee, Operating Lease, Discount Rate			3.75%		3.75%		3.76%
Operating Lease, Weighted Average Remaining Lease Term			5 years 328 days		5 years 328 days		6 years 146 days
Manhattan Drug Company [Member]
Payments for Rent		$ 533
AgroLabs [Member]
Area of Real Estate Property | ft²	2,700
Payments for Rent	$ 27
Chairman, Chief Executive Office and Major Stockholder [Member]
Percent of Ownership for Warehouse and Office Facilities Leased					100.00%
Vitamin Realty LLC [Member]
Operating Leases, Rent Expense, Net, Total			$ 220	$ 219	$ 431	$ 421
Due to Related Parties, Total			71		71		$ 67
Operating Lease, Liability, Total			$ 3,021		$ 3,021		$ 3,243
Vitamin Realty LLC [Member] | Operating Lease Renewed for Office Space [Member]
Lessee, Operating Lease, Term of Contract			1 year		1 year
Lessee, Operating Lease, Liability, Annual Commitment					$ 25
Minimum [Member]
Lessee, Lease, Term of Contract					1 year
Minimum [Member] | Manhattan Drug Company [Member]
Area of Real Estate Property | ft²		74,898
Maximum [Member]
Lessee, Lease, Term of Contract					8 years
Maximum [Member] | Manhattan Drug Company [Member]
Area of Real Estate Property | ft²		76,161

Note 6 - Leases and Other Com_4

Note 6 - Leases and Other Commitments and Contingencies - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Operating lease costs	$ 167	$ 169	$ 339	$ 332
Amortization of right-of use assets	2	16	29	33
Interest on operating lease liabilities	3	3	8	7
Total finance lease cost	5	19	37	40
Unrelated Party [Member]
Operating lease costs	25	27	56	49
Amortization of right-of use assets	2	16	29	33
Interest on operating lease liabilities	3	3	8	7
Total finance lease cost	5	19	37	40
Vitamin Realty LLC [Member]
Operating lease costs	142	142	283	283
Amortization of right-of use assets
Interest on operating lease liabilities
Total finance lease cost

Note 6 - Leases and Other Com_5

Note 6 - Leases and Other Commitments and Contingencies - Leases and Commitments (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Operating lease right-of-use assets	$ 3,052	$ 3,284
Current portion operating lease obligations	478	470
Operating lease obligations	2,580	2,822
Remaining cash commitment	3,425	3,719
Machinery and Equipment Leases [Member]
Operating lease right-of-use assets	21	26
Current portion operating lease obligations	11	11
Operating lease obligations	10	15
Remaining cash commitment	22	27
Office Equipment Leases [Member]
Operating lease right-of-use assets	17	22
Current portion operating lease obligations	9	9
Operating lease obligations	7	14
Remaining cash commitment	18	24
Vitamin Realty LLC [Member]
Operating lease right-of-use assets	3,014	3,236
Current portion operating lease obligations	458	450
Operating lease obligations	2,563	2,793
Remaining cash commitment	$ 3,385	$ 3,668

Note 6 - Leases and Other Com_6

Note 6 - Leases and Other Commitments and Contingencies - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating cash flows from operating leases	$ 330	$ 334
Operating cash flows from finance leases	8	7
Financing cash flows from finance lease obligations	115	101
Unrelated Party [Member]
Operating cash flows from operating leases	47	49
Operating cash flows from finance leases	8	7
Financing cash flows from finance lease obligations	115	101
Vitamin Realty LLC [Member]
Operating cash flows from operating leases	283	285
Operating cash flows from finance leases
Financing cash flows from finance lease obligations

Note 6 - Leases and Other Com_7

Note 6 - Leases and Other Commitments and Contingencies - Minimum Rental Commitment for Long-term Non-cancelable Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
2020, remaining capital lease	$ 83
2020, remaining total	377
2021, Capital Lease Obligation	77
2021, Total	663
2022, Capital Lease Obligation
2022, Total	573
2023, Capital Lease Obligation
2023, Total	565
2024, Capital Lease Obligation
2024, Total	563
2025, Capital Lease Obligation
2025, Total	533
Thereafter, Capital Lease Obligation
Thereafter, Total	311
Total minimum lease payments, Capital Lease Obligation	160
Total minimum lease payments, Total	3,585
Imputed interest, Capital Lease Obligation	(6)
Imputed interest, Total	(373)
Total, Capital Lease Obligation	154
Total	3,212
Vitamin Realty LLC [Member]
2020, remaining operating lease	283
2021, Operating Lease	565
2022, Operating Lease	565
2023, Operating Lease	565
2024, Operating Lease	563
2025, Operating Lease	533
Thereafter, Operating Lease	311
Total minimum lease payments, Operating Lease	3,385
Imputed interest, Operating Lease	(364)
Total, Operating Lease	3,021	$ 3,243
Unrelated Party [Member]
2020, remaining operating lease	11
2021, Operating Lease	21
2022, Operating Lease	8
2023, Operating Lease
2024, Operating Lease
2025, Operating Lease
Thereafter, Operating Lease
Total minimum lease payments, Operating Lease	40
Imputed interest, Operating Lease	(3)
Total, Operating Lease	$ 37

Note 8 - Segment Information _3

Note 8 - Segment Information and Disaggregated Revenue (Details Textual)	3 Months Ended		6 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Number of Reportable Segments			3
Revenue from Contract with Customer, Including Assessed Tax	$ 14,197,000	$ 12,001,000	$ 25,603,000	$ 22,305,000
Europe [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 2,319	$ 1,274	$ 4,345	$ 2,513

Note 8 - Segment Information _4

Note 8 - Segment Information and Disaggregated Revenue - Operations by Business Segment (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Sales, net	$ 14,197,000	$ 12,001,000	$ 25,603,000	$ 22,305,000
Gross Profit	2,026,000	1,330,000	3,425,000	2,549,000
Depreciation	69,000	66,000	160,000	132,000
Capital Expenditures	43,000	269,000	101,000	287,000
Contract Manufacturing [Member]
Sales, net	13,804,000	11,756,000	24,788,000	21,608,000
Gross Profit	1,927,000	1,246,000	3,177,000	2,328,000
Depreciation	69,000	66,000	159,000	131,000
Capital Expenditures	43,000	269,000	101,000	287,000
Branded Proprietary Products [Member]
Sales, net	2,000	60,000	14,000	138,000
Gross Profit	(27,000)	21,000	(30,000)	42,000
Depreciation
Capital Expenditures
Other Nutraceutical Business [Member]
Sales, net	391,000	185,000	801,000	559,000
Gross Profit	126,000	63,000	278,000	179,000
Depreciation			1,000	1,000
Capital Expenditures
UNITED STATES
Sales, net	11,878,000	10,727,000	21,258,000	19,792,000
UNITED STATES | Contract Manufacturing [Member]
Sales, net	11,501,000	10,498,000	20,502,000	19,153,000
UNITED STATES | Branded Proprietary Products [Member]
Sales, net	2,000	48,000	4,000	119,000
UNITED STATES | Other Nutraceutical Business [Member]
Sales, net	375,000	181,000	752,000	520,000
Non-US [Member]
Sales, net	2,319,000	1,274,000	4,345,000	2,513,000
Non-US [Member] | Contract Manufacturing [Member]
Sales, net	2,303,000	1,258,000	4,286,000	2,455,000
Non-US [Member] | Branded Proprietary Products [Member]
Sales, net		12,000	10,000	19,000
Non-US [Member] | Other Nutraceutical Business [Member]
Sales, net	$ 16,000	$ 4,000	$ 49,000	$ 39,000

Note 8 - Segment Information _5

Note 8 - Segment Information and Disaggregated Revenue - Total Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Total Assets	$ 19,971	$ 19,790
Contract Manufacturing [Member]
Total Assets	18,017	17,580
Branded Proprietary Products [Member]
Total Assets	395	427
Other Nutraceutical Business [Member]
Total Assets	$ 1,559	$ 1,783